TRIAL DETAIL
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Active, not recruiting |
|||
Phase: |
1 |
Start Date 10/01/2013 |
Age of Trial (yrs) 10.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PD-1 + LAG-3 Inhibitor |
|||
Strategy: |
||||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CA224-020 |
|||
Sponsor: |
Bristol-Myers Squibb |
|||
Patient Contact: |
Clinical.Trials@bms.com
First line of the email MUST contain NCT# and Site #.
|
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Inclusion Criteria: Part A, Dose Escalation: Advanced (metastatic and/or unresectable) and incurable solid tumors, naive to Immune Cell Modulating Antibody Regimens (ICMARs) Part B, Dose Escalation: Advanced (metastatic and/or unresectable) and incurable solid tumors, |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
5841 S. Maryland Ave |
Chicago |
IL |
60637 |
USA |
|
Baltimore |
MD |
21231 |
USA |
||
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
1275 York Ave |
New York |
NY |
10065 |
USA |
|
Portland |
OR |
97213 |
USA |
||
4100 John R |
Detroit |
MI |
48201 |
USA |
|
Helsinki |
FIN-00029 |
Finland |
|||
Toulouse |
31052 |
France |
|||
Napoli |
80131 |
Italy |
|||
119-129 |
Barcelona |
08035 |
Spain |
||
Plamplona |
Spain |
||||
Lausanne |
CH-1011 |
Switzerland |
|||
Seattle |
WA |
98109 |
USA |
||
Vienna |
1090 |
Austria |